NeuBase Therapeutics, Inc.: Nasdaq/NYSE listing notice — NeuBase Therapeutics receives Nasdaq delisting notice; trading to be suspended May 13 amid planned dissolution

NeuBase Therapeutics, Inc.

Nasdaq notified NeuBase on May 2, 2024 that it failed to regain compliance with $1.00 minimum bid price requirement.
Company does not intend to appeal; trading suspension expected at open on May 13, 2024, followed by Form 25-NSE filing.
Board previously approved liquidation and dissolution, subject to stockholder vote at special meeting on May 13, 2024.
In light of planned dissolution, company will not seek an appeal of the delisting determination.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

NeuBase Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

May 2, 2024, the Staff notified the Company that it has not regained compliance with the Minimum Bid Price Requirement (the “Delisting Determination”) and that it is ineligible for a second 180 calendar day period to regain compliance as it did not provide information regarding its intent to cure the bid price deficiency. The Staff informed the Company that unless it requests an appeal of the Delisting Determination to a Hearings Panel by May 9, 2024, the Company’s common stock will be scheduled for delisting from the Nasdaq Capital Market and will be suspended at the opening of business on Ma

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-24-056957

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.